Read Articles from the Web about the Company Sorted by Complexity
Dexmethylphenidate controlled release - Cingulate Therapeutics ... application to US FDA (Cingulate Therapeutics, pipeline, March 2020) Updated 17 Mar 2020.
Oct 24, 2019 — Cingulate Therapeutics. Information provided by (Responsible Party):. Cingulate Therapeutics. Study Details; Tabular View · Study Results ...
Cingulate Therapeutics primary focus is to develop and commercialize the CTx ... in ADHD,” added Shane Schaffer, Chairman and CEO of Cingulate Therapeutics.
View Cingulate Therapeutics LLC, including Executives & Employees and Board of ... Chairman & Chief Executive Officer at Cingulate Therapeutics LLC.
Cingulate Therapeutics Revenue: $2.00 Million | Employees: 16 | Industry: ... Who is the Chairman and Chief Executive Officer of Cingulate Therapeutics?
Cadent Therapeutics is rapidly advancing a pipeline of novel allosteric . ... Cingulate Therapeutics. Business Area(s):. Neurobiology. Description:.
Aug 17, 2021 — The pipeline guide reviews pipeline therapeutics for Attention Deficit ... Cennerv Pharma (S) Pte Ltd; Cingulate Therapeutics LLC ...
Sep 24, 2014 — Cingulate Therapeutics (CTx) is a privately held biopharmaceutical company focused on the development of new products for the treatment of ...
Cingulate Therapeutics (CTx) is a privately held, clinical-stage biopharmaceutical company focused on the development of products for the treatment of ...
CINGULATE THERAPEUTICS (CTx) is a privately held, pharmaceutical company, headquartered in Morristown, NJ. At present, CTx is developing TWO (2) assets for ...
4 days ago — The firm is using its proprietary Precision Timed Release (PTR) drug delivery platform technology to advance a pipeline of next-generation ...
Jan 18, 2021 — In an interview with HCPLive®, Matthew Brams, MD, Chief Medical Officer of Cingulate Therapeutics, and Shane Schaffer, PharmD, ...
by AC Childress · 2020 · Cited by 6 — (ADHD) seek treatment primarily due to functional impair- ment (e.g., strained relations, ... Labs, Arbor Pharmaceuticals, Cingulate Therapeutics, Ironshore.
Oct 26, 2020 — Cingulate's two lead assets in the $18B ADHD market include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) –both first-line ...
Laurie's experience in all aspects of branded pharmaceutical life cycle management from clinical drug development through commercialisation is a major asset, ...